The Modelling-Informed Medicine Centre will create computer models or digital twins of organs and diseases to better understand how diseases of the lungs, liver, and kidneys progress, to discover and ...

Asciminib is the first-in-class allosteric inhibitor that specifically binds the BCR::ABL1 myristoyl pocket used to treat patients with Chronic Myeloid Leukemia (CML). The global incidence rate of CML ...

Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its Simcyp® Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions ...

Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of ...

Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals in 2025, more than half (26) were designated as rare disease (orphan) ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development process for industry and patients. Our two companies are applying AI in ...

Leerink Global Healthcare Conference 2026 March 9, 2026 8:00 AM EDTCompany ParticipantsJohn Gallagher - SVP, Principal ...

Pharmacometrics has long provided a scientific foundation for quantitative decision-making in drug development and therapeutics. Yet, much of its ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 1:00 PM EDTCompany ParticipantsJohn Gallagher - SVP, ...